Daniel Doheny
Overview
Explore the profile of Daniel Doheny including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Doheny D, Sirkisoon S, Carpenter R, Aguayo N, Regua A, Anguelov M, et al.
Oncogene
. 2024 Apr;
43(23):1811.
PMID: 38678124
No abstract available.
2.
Doheny D, Manore S, Sirkisoon S, Zhu D, Aguayo N, Harrison A, et al.
Cancers (Basel)
. 2022 Sep;
14(17).
PMID: 36077791
The goal of this study is to identify pharmacological inhibitors that target a recently identified novel mediator of breast cancer brain metastasis (BCBM), truncated glioma-associated oncogene homolog 1 (tGLI1). Inhibitors...
3.
Rimkus T, Arrigo A, Zhu D, Carpenter R, Sirkisoon S, Doheny D, et al.
Cancer Lett
. 2022 Feb;
531:124-135.
PMID: 35167936
Whether tumor suppressor candidate 2 (TUSC2) plays an important role in glioblastoma (GBM) progression is largely unknown. Whether TUSC2 undergoes polyubiquitination is unknown. Herein, we report that TUSC2 protein expression...
4.
Regua A, Arrigo A, Doheny D, Wong G, Lo H
Cancer Lett
. 2021 Jun;
516:73-83.
PMID: 34090924
Transgenic breast cancer mouse models are critical tools for preclinical studies of human breast cancer. Genetic editing of the murine mammary gland allows for modeling of abnormal genetic events frequently...
5.
Sirkisoon S, Carpenter R, Rimkus T, Doheny D, Zhu D, Aguayo N, et al.
Oncogene
. 2021 Mar;
40(12):2338.
PMID: 33654200
No abstract available.
6.
Doheny D, Manore S, Wong G, Lo H
Cells
. 2020 Sep;
9(9).
PMID: 32957513
The hedgehog (HH) signaling pathway regulates normal cell growth and differentiation. As a consequence of improper control, aberrant HH signaling results in tumorigenesis and supports aggressive phenotypes of human cancers,...
7.
Doheny D, Sirkisoon S, Carpenter R, Aguayo N, Regua A, Anguelov M, et al.
Oncogene
. 2020 Sep;
39(42):6589-6605.
PMID: 32929154
Triple-negative breast cancer (TNBC) and HER2-positive breast cancer are particularly aggressive and associated with unfavorable prognosis. TNBC lacks effective treatments. HER2-positive tumors have treatment options but often acquire resistance to...
8.
Regua A, Doheny D, Arrigo A, Lo H
Discov Med
. 2020 Jan;
28(154):195-203.
PMID: 31928627
Tropomyosin receptor kinases (TRKs) were first identified in 1986 when NTRK1 was discovered as part of an oncogenic fusion gene in colorectal cancer and the discovery of NTRK2 and NTRK3...
9.
Beames T, Moreau M, Roberts L, Mansouri K, Haider S, Smeltz M, et al.
Toxicol Appl Pharmacol
. 2019 Nov;
387:114774.
PMID: 31783037
Chemical risk assessment relies on toxicity tests that require significant numbers of animals, time and costs. For the >30,000 chemicals in commerce, the current scale of animal testing is insufficient...
10.
Sirkisoon S, Carpenter R, Rimkus T, Doheny D, Zhu D, Aguayo N, et al.
Oncogene
. 2019 Aug;
39(1):64-78.
PMID: 31462709
Mechanisms for breast cancer metastasis remain unclear. Whether truncated glioma-associated oncogene homolog 1 (TGLI1), a transcription factor known to promote angiogenesis, migration and invasion, plays any role in metastasis of...